Approval status
Bremelanotide is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. It is not FDA-approved to treat erectile dysfunction in men.
Telehealth use in men
A provider may discuss or prescribe a compounded product under medical judgment, but marketing should not imply FDA approval for male ED.
Questions to ask
Why this treatment rather than an approved PDE5 inhibitor?
Is the product compounded, and by which pharmacy?
What route and dose are prescribed?
What are the blood-pressure, nausea, pigmentation, and interaction risks?